The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,022
Juratli, T. A., Stasik, S., Zolal, A., Schuster, C., Richter, S., Daubner, D., Juratli, M. A., Thowe, R., Hennig, S., Makina, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3717 · Cited by 107
Xiong, A., Zhang, J., Chen, Y., Zhang, Y., & Yang, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104239 · Cited by 103
Schulz, J., Hartz, A. M. S., & Bauer, B. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000025 · Cited by 118
Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents
Biddlestone-Thorpe, L., Marchi, N., Guo, K., Ghosh, C., Janigro, D., Valerie, K. C., & Yang, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.014 · Cited by 103
Cancer Immunoediting in Malignant Glioma
Dunn, G. P., Fecci, P. E., & Curry, W. T. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31824f840d · Cited by 99
Han, X., Li, R., Zhang, W., Yang, X., Wheeler, C. G., Friedman, G. K., Province, P., Ding, Q., You, Z., Fathallah‐Shaykh, H. M., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1419-0 · Cited by 103
Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire
Sims, J. S., Grinshpun, B., Feng, Y., Ung, T. H., Neira, J. A., Samanamud, J. L., Canoll, P., Shen, Y., Sims, P. A., & Bruce, J. N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601012113 · Cited by 103
Biomolecular Events in Cancer Revealed by Attractor Metagenes
Cheng, W., Yang, T.-H. O., & Anastassiou, D. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002920 · Cited by 104
Nakano, I., Garnier, D., Minata, M., & Rak, J. W. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.02.011 · Cited by 106
Notching on Cancer’s Door: Notch Signaling in Brain Tumors
Teodorczyk, M., & Schmidt, M. H. H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00341 · Cited by 108
A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma
Kondapalli, K. C., Llongueras, J. P., Capilla‐González, V., Prasad, H., Hack, A., Smith, C. L., Guerrero‐Cazares, H., Quiñones‐Hinojosa, A., & Rao, R. (2015) · Nature Communications · doi:10.1038/ncomms7289 · Cited by 109
Sandberg, C. J., Altschuler, G. M., Jeong, J., Kierulf-Vieira, K. S., Stangeland, B., Murrell, W. G., Grasmo-Wendler, U.-H., Myklebost, O., Helseth, E., Vik-Mo, E. O., et al. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.06.004 · Cited by 104
Proteomics of gliomas: Initial biomarker discovery and evolution of technology
Kalinina, J., Peng, J., Ritchie, J., & Meir, E. G. V. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor078 · Cited by 105
A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes
Giachino, C., Boulay, J., Ivánek, R., Alvarado, A. G., Tostado, C., Lugert, S., Tchorz, J. S., Coban, M., Mariani, L., Bettler, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.008 · Cited by 105
Martínez-Ledesma, E., Verhaak, R. G. W., & Treviño, V. (2015) · Scientific Reports · doi:10.1038/srep11966 · Cited by 103
Self-citationEndogenous GABAA receptor activity suppresses glioma growth
Blanchart, A., Fernando, R. N., Häring, M., Assaife‐Lopes, N., Romanov, R. A., Andäng, M., Harkany, T., & Ernfors, P. (2016) · Oncogene · doi:10.1038/onc.2016.245 · Cited by 101
Oh, S., Yeom, J., Cho, H. J., Kim, J.-H., Yoon, S., Kim, H.-D., Sa, J. K., Ju, S., Lee, H., Oh, M. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17139-y · Cited by 100
The white matter is a pro-differentiative niche for glioblastoma
Brooks, L. J., Clements, M., Burden, J. J., Kocher, D., Richards, L., Devesa, S. C., Zakka, L., Woodberry, M., Ellis, M. J., Jaunmuktane, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22225-w · Cited by 106
Gerritsen, J. K. W., Zwarthoed, R. H., Kilgallon, J. L., Nawabi, N. L. A., Jessurun, C. A. C., Versyck, G., Pruijn, K. P., Fisher, F. L., Larivière, E., Solie, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00213-3 · Cited by 111
Neuronal and tumourigenic boundaries of glioblastoma plasticity
Silva, M. I. D., Stringer, B. W., & Bardy, C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.010 · Cited by 110
Chang, H., Han, J., Borowsky, A. D., Loss, L., Gray, J. W., Spellman, P. T., & Parvin, B. (2012) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2012.2231420 · Cited by 103
Self-citationMET inhibition overcomes radiation resistance of glioblastoma stem‐like cells
Bacco, F. D., D'Ambrosio, A., Casanova, E., Orzan, F., Neggia, R., Albano, R., Verginelli, F., Cominelli, M., Poliani, P. L., Luraghi, P., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505890 · Cited by 105
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
Brown, D. V., Daniel, P. M., D’Abaco, G. M., Gogos, A., Ng, W., Morokoff, A. P., & Mantamadiotis, T. (2015) · Oncotarget · doi:10.18632/oncotarget.3365 · Cited by 104
Transforming growth factor-β pathway activity in glioblastoma
Frei, K., Gramatzki, D., Tritschler, I., Schroeder, J. J., Espinoza, L., Rushing, E. J., & Weller, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3467 · Cited by 101
Integration and analysis of genome-scale data from gliomas
Riddick, G., & Fine, H. A. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.100 · Cited by 101
Rockne, R. C., Trister, A. D., Jacobs, J., Hawkins-Daarud, A. J., Neal, M. L., Hendrickson, K. R. G., Mrugała, M. M., Rockhill, J. K., Kinahan, P. E., Krohn, K. A., et al. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.1174 · Cited by 99
Kurscheid, S., Bady, P., Sciuscio, D., Samaržija, I., Shay, T., Vassallo, I., Criekinge, W. V., Daniel, R. T., van den Bent, M. J., Marosi, C., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0583-7 · Cited by 100
Naeini, K. M., Pope, W. B., Cloughesy, T. F., Harris, R. J., Lai, A., Eskin, A., Chowdhury, R., PHILLIPS, H. S., Nghiemphu, P. L., Behbahanian, Y., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not008 · Cited by 100
Shi, Y., Chen, C., Zhang, X., Liu, Q., Xu, J., Zhang, H., Yao, X., Jiang, T., He, Z., Ren, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2284 · Cited by 101
Vitucci, M., Hayes, D. N., & Miller, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606031 · Cited by 101
Self-citationTargeting BET bromodomain proteins in solid tumors
Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F., & Munshi, H. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9804 · Cited by 103
Müller, S., Liu, S. J., Lullo, E. D., Malatesta, M., Pollen, A. A., Nowakowski, T. J., Kohanbash, G., Aghi, M. K., Kriegstein, A. R., Lim, D. A., et al. (2016) · Molecular Systems Biology · doi:10.15252/msb.20166969 · Cited by 102
Advances in epigenetic glioblastoma therapy
Lee, D. H., Ryu, H.-W., Won, H.-R., & Kwon, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14612 · Cited by 101
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Lee, Y., Koh, J., Kim, S., Won, J., Park, C., Choi, S. H., & Park, S. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0465-1 · Cited by 101
Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment
Liu, C.-A., Chang, C., Hsueh, K.-W., Su, H.-L., Chiou, T., Lin, S., & Harn, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041115 · Cited by 104
Wang, Z., Wang, Z., Zhang, C., Liu, X., Li, G., Liu, S., Sun, L., Liang, J., Hu, H., Liu, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13744 · Cited by 101
Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma
Caragher, S. P., Shireman, J. M., Huang, M., Miska, J. M., Atashi, F., Baisiwala, S., Park, C. H., Saathoff, M. R., Warnke, L., Xiao, T., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1589-18.2018 · Cited by 101
Self-citationA cloud-based workflow to quantify transcript-expression levels in public cancer compendia
Tatlow, P., & Piccolo, S. (2016) · Scientific Reports · doi:10.1038/srep39259 · Cited by 101
The Role of Hypoxia in Glioblastoma Radiotherapy Resistance
Chédeville, A. L., & Madureira, P. A. (2021) · Cancers · doi:10.3390/cancers13030542 · Cited by 101
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations
Magnus, N., Garnier, D., Meehan, B., McGraw, S., Lee, T. H., Caron, M., Bourque, G., Milsom, C., Jabado, N., Trasler, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314118111 · Cited by 102
Valente, V., Serafim, R. B., de Oliveira, L. C., Adorni, F. S., Torrieri, R., Tirapelli, D. P. D. C., Espreáfico, E. M., Oba‐Shinjo, S. M., Marie, S. K. N., Paçó‐Larson, M. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062200 · Cited by 100
Hamblett, K. J., Kozlosky, C. J., Siu, S., Chang, W., Liu, H., Foltz, I. N., Trueblood, E. S., Meininger, D. P., Arora, T., Twomey, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1078 · Cited by 101
Immunotherapy for Brain Cancer: Recent Progress and Future Promise
Jackson, C. M., Lim, M. K., & Drake, C. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2057 · Cited by 102
Ellis, H. P., Greenslade, M., Powell, B., Spiteri, I., Sottoriva, A., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00251 · Cited by 105
Polymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 104
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 105
Wei, C., Wang, B., Peng, D., Zhang, X., Li, Z., Luo, L., He, Y., Liang, H., Du, X., Li, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849592 · Cited by 100
An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
Rodriguez, S. M. B., Kamel, A. E., Ciubotaru, G. V., Onose, G., Sevastre, A.-S., Sfredel, V., Dănoiu, S., Dricu, A., & Tătăranu, L. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311110 · Cited by 108
Neuron–oligodendroglial interactions in health and malignant disease
Taylor, K. R., & Monje, M. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00744-3 · Cited by 106
Molecular Heterogeneity of Glioblastoma and its Clinical Relevance
Éder, K., & Kálmán, B. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9833-3 · Cited by 100
Chen, G., Kong, J., Tucker‐Burden, C., Anand, M., Rong, Y., Rahman, F., Moreno, C. S., Meir, E. G. V., Hadjipanayis, C. G., & Brat, D. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3703 · Cited by 100
Jiang, Y., & Uhrbom, L. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.658976 · Cited by 100
Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma
Li, X., Liu, Y., Granberg, K. J., Wang, Q., Moore, L. M., Ji, P., Gumin, J., Sulman, E. P., Calin, G. A., Haapasalo, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.98 · Cited by 99
A practical review of prognostic correlations of molecular biomarkers in glioblastoma
Karsy, M. J., Neil, J. A., Guan, J., Mahan, M. A., Colman, H., & Jensen, R. L. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14755 · Cited by 98
Erdem‐Eraslan, L., van den Bent, M. J., Hoogstrate, Y., Naz-Khan, H., Stubbs, A., van der Spek, P. J., Böttcher, R., Gao, Y., de Wit, M., Taal, W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0776 · Cited by 98
Differential response of patient-derived primary glioblastoma cells to environmental stiffness
Grundy, T. J., Leon, E. D., Griffin, K. R., Stringer, B. W., Day, B. W., Fabry, B., Cooper-White, J. J., & O’Neill, G. M. (2016) · Scientific Reports · doi:10.1038/srep23353 · Cited by 99
Relationship between Glioblastoma Heterogeneity and Survival Time: An MR Imaging Texture Analysis
Liu, Y., Xu, X., Yin, L., Zhang, X., Li, L. C., & Lu, H. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5279 · Cited by 99
Pawłowska, E., Szczepańska, J., Szatkowska, M., & Błasiak, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030889 · Cited by 100
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Stathias, V., Jermakowicz, A. M., Maloof, M. E., Forlin, M., Walters, W. M., Suter, R. K., Durante, M. A., Williams, S. L., Harbour, J. W., Volmar, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07659-z · Cited by 101
Self-citationPeñaranda-Fajardo, N. M., Meijer, C., Liang, Y., Dijkstra, B. M., Aguirre‐Gamboa, R., den Dunnen, W. F. A., & Kruyt, F. A. E. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1934-1 · Cited by 99
Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
Tilak, M., Holborn, J., New, L. A., Lalonde, J., & Jones, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041831 · Cited by 105
Stem cell signature in glioblastoma: therapeutic development for a moving target
Nakano, I. (2014) · Journal of neurosurgery · doi:10.3171/2014.9.jns132253 · Cited by 99
Integrative multi-omics module network inference with lemon-tree
Bonnet, E., Calzone, L., & Michoel, T. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003983 · Cited by 98
STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma
Lau, J., Ilkhanizadeh, S., Wang, S., Miroshnikova, Y. A., Salvatierra, N. A., Wong, R. A., Schmidt, C., Weaver, V. M., Weiss, W. A., & Persson, A. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3331 · Cited by 101
Kitambi, S. S., Toledo, E. M., Usoskin, D., Wee, S., Harisankar, A., Svensson, R., Sigmundsson, K., Kalderén, C., Niklasson, M., Kundu, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.021 · Cited by 100
RetractedChakraborty, S., Li, L., Puliyappadamba, V. T., Guo, G., Hatanpaa, K. J., Mickey, B., Souza, R. F., Vo, P., Herz, J., Chen, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6811 · Cited by 101
Genetic modeling of gliomas in mice: New tools to tackle old problems
Hambardzumyan, D., Parada, L. F., Holland, E. C., & Charest, A. (2011) · Glia · doi:10.1002/glia.21142 · Cited by 107
Ricklefs, F. L., Mineo, M., Rooj, A. K., Nakano, I., Charest, A., Weissleder, R., Breakefield, X. O., Chiocca, E. A., Godlewski, J. A., & Bronisz, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3432 · Cited by 100
Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells
Binda, E., Visioli, A., Giani, F., Trivieri, N., Palumbo, O., Restelli, S., Dezi, F., Mazza, T., Fusilli, C., Legnani, F. G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1693 · Cited by 99
Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Oizel, K., Chauvin, C., Oliver, L., Gratas, C., Geraldo, F., Jarry, U., Scotet, E., Rabé, M., Alves‐Guerra, M., Teusan, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3102 · Cited by 108
Newman, J. P. A., Wang, G., Arima, K., Guan, S. P., Waters, M. R., Cavenee, W. K., Pan, E., Aliwarga, E., Chong, S. T., Kok, C. Y. L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01392-9 · Cited by 100
Rhee, J., Jung, Y. C., Kim, K. R., Yoo, J., Kim, J., Lee, Y., Ko, Y. H., Lee, H. H., Cho, B. C., & Kim, T. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0201 · Cited by 98
Nayak, L., & Reardon, D. A. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000554 · Cited by 100
Zhang, G., Chen, L., Khan, A. A., Li, B., Gu, B., Lin, F., Su, X., & Yan, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31329 · Cited by 98
Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues
Zhou, D., Alver, B., Li, S., Hlady, R. A., Thompson, J. J., Schroeder, M. A., Lee, J., Qiu, J., Schwartz, P. H., Sarkaria, J. N., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1420-6 · Cited by 97
Self-citationGuilhamon, P., Chesnelong, C., Kushida, M. M., Nikolić, A., Singhal, D., MacLeod, G. D. A. H., Tonekaboni, S. A. M., Cavalli, F. M. G., Arlidge, C., Rajakulendran, N., et al. (2021) · eLife · doi:10.7554/elife.64090 · Cited by 104
Microglia and astrocyte involvement in neurodegeneration and brain cancer
Vandenbark, A. A., Offner, H., Matejuk, S., & Matejuk, A. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02355-0 · Cited by 101
Dewdney, B., Jenkins, M. R., Best, S. A., Freytag, S., Prasad, K., Holst, J., Endersby, R., & Johns, T. G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01637-8 · Cited by 107
Mazzacurati, L., Marzulli, M., Reinhart, B., Miyagawa, Y., Uchida, H., Goins, W. F., Li, A., Kaur, B., Caligiuri, M. A., Cripe, T. P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.177 · Cited by 98
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis
Ortiz, B., Fabius, A. W. M., Wu, W., Pedraza, A. M., Brennan, C., Schultz, N. D., Pitter, K. L., Bromberg, J., Huse, J. T., Holland, E. C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401952111 · Cited by 97
Self-citationEmerging Biomarkers in Glioblastoma
McNamara, M. G., Sahebjam, S., & Mason, W. (2013) · Cancers · doi:10.3390/cancers5031103 · Cited by 95
Serão, N. V. L., Delfino, K. R., Southey, B. R., Beever, J. E., & Rodriguez‐Zas, S. L. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-49 · Cited by 97
Glioblastoma: Molecular Analysis and Clinical Implications
Huse, J. T., Holland, E. C., & DeAngelis, L. M. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-100711-143028 · Cited by 96
Tentori, L., Ricci‐Vitiani, L., Muzi, A., Ciccarone, F., Pelacchi, F., Calabrese, R., Runci, D., Pallini, R., Caiafa, P., & Graziani, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-151 · Cited by 98
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Shiina, S., Ohno, M., Ohka, F., Kuramitsu, S., Yamamichi, A., Kato, A., Motomura, K., Tanahashi, K., Yamamoto, T., Watanabe, R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0060 · Cited by 97
Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma
Nizamutdinov, D., Stock, E. M., Dandashi, J. A., Vasquez, E. A., Mao, Y. Q., Dayawansa, S., Zhang, J., Wu, E., Fonkem, E., & Huang, J. H. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.09.104 · Cited by 97
Proteoglycans in brain development and pathogenesis
Schwartz, N. B., & Domowicz, M. S. (2018) · FEBS Letters · doi:10.1002/1873-3468.13026 · Cited by 99
Lane, R., Simon, T., Vintu, M., Solkin, B., Koch, B., Stewart, N. A., Benstead-Hume, G., Pearl, F. M. G., Critchley, G. R., Stebbing, J., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0560-x · Cited by 98
Wang, X., Zhou, R., Xiong, Y., Zhou, L., Yan, X., Wang, M., Fan, L., Xie, C., Zhang, Y., Huang, Z., et al. (2021) · Cell Research · doi:10.1038/s41422-020-00451-z · Cited by 99
Duraj, T., Garcia‐Romero, N., Carrión-Navarro, J., Madurga, R., de Méndivil, A. O., Prat-Acín, R., García‐Cañamaque, L., & Ayuso‐Sacido, Á. (2021) · Cells · doi:10.3390/cells10020202 · Cited by 99
Lam, K. H. B., Leon, A. J., Hui, W., Lee, S. C.-E. S., Batruch, I., Faust, K., Klekner, Á., Hutóczki, G., Koritzinsky, M., Richer, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27667-w · Cited by 97
Targeting fatty acid metabolism in glioblastoma
Miska, J. M., & Chandel, N. S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163448 · Cited by 99
Autophagy in Brain Tumors: A New Target for Therapeutic Intervention
Kaza, N., Kohli, L., & Roth, K. A. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00544.x · Cited by 98
β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells
Nàger, M., Bhardwaj, D., Cantí, C., Medina, L. M., Nogués, P., & Herreros, J. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/192362 · Cited by 101
Parkin Pathway Activation Mitigates Glioma Cell Proliferation and Predicts Patient Survival
Yeo, C. W. S., Ng, F., Chai, C., Tan, J. M. M., Koh, G. R. H., Chong, Y. K., Koh, L., Foong, C. S. F., Sandanaraj, E., Holbrook, J. D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3060 · Cited by 101
Somatic mutations associated with MRI-derived volumetric features in glioblastoma
Gutman, D. A., Dunn, W. D., Großmann, P., Cooper, L., Holder, C. A., Ligon, K. L., Alexander, B. M., & Aerts, H. J. W. L. (2015) · Neuroradiology · doi:10.1007/s00234-015-1576-7 · Cited by 94
Aberrant Expression of Interleukin-1β and Inflammasome Activation in Human Malignant Gliomas
Tarassishin, L., Casper, D., & Lee, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103432 · Cited by 99
The ketogenic diet for the treatment of malignant glioma
Woolf, E. C., & Scheck, A. C. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046797 · Cited by 96
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis
Kim, Y. W., Koul, D., Kim, S. H., Lucio-Eterovic, A. K., Freire, P. R., Yao, J. C., Wang, J., Almeida, J. S., Aldape, K., & Yung, W. K. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not024 · Cited by 98
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
